Infectious diseases specialists diagnose and treat infections from bacteria, viruses, fungi, and parasites, focusing on fevers, antibiotics, and vaccines.
Send us all your questions or requests, and our expert team will assist you.
Historically, the treatment for Ebola Virus Disease was strictly supportive. The prevailing medical philosophy was to manage the symptoms and hope the patient’s immune system could overcome the viral assault. This often occurred in resource-poor settings where “treatment” was limited to oral rehydration and isolation. However, the 2014-2016 and 2018-2020 outbreaks catalyzed a paradigm shift. Today, the management of Ebola involves a sophisticated combination of aggressive supportive care and targeted molecular therapeutics. This shift has transformed Ebola from a largely untreatable condition into one where survival is significantly improved with timely intervention.
The foundation of Ebola management remains aggressive supportive care. The virus causes massive fluid losses through vomiting and diarrhea, leading to hypovolemic shock. Reversing this state is the primary clinical objective.
The implementation of “optimized supportive care” — treating Ebola patients with the same rigor as critical care patients in developed nations — has been shown to reduce mortality significantly, independent of specific antiviral drugs.
The most significant advancement in Ebola treatment involves the use of monoclonal antibodies (mAbs). These are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on the virus. Two specific treatments have demonstrated high efficacy in randomized clinical trials:
These therapeutics are most effective when administered early in the disease course. Data from the PALM trial in the DRC showed that survival rates were significantly higher in patients treated with these drugs than in those treated with older experimental agents such as ZMapp.
Other antiviral drugs, such as Remdesivir, were initially developed for Ebola. Remdesivir works by interfering with the viral RNA polymerase, essentially gumming up the virus’s replication machinery. While Remdesivir is now widely known for its use in COVID-19, trials in Ebola showed it was less effective than the monoclonal antibody treatments mentioned above. Consequently, it is no longer recommended as first-line therapy for Ebola Zaire. However, research continues on small-molecule antivirals that could be easier to distribute than antibodies that require cold chain storage.
In the absence of specific drugs, transfusing blood plasma from recovered Ebola patients (convalescent plasma) into sick patients was historically used. The theory is that the antibodies in the survivor’s blood would help the sick patient fight the virus. However, rigorous studies have yielded mixed results regarding its efficacy. While the concept is biologically sound and rooted in regenerative principles of transferring immunity, the variability in antibody titers (concentration) in donor plasma makes standardization difficult. Therefore, monoclonal antibodies, which offer a consistent and potent dose, have superseded this approach.
Advanced care involves managing the severe complications of organ failure.
Treatment extends beyond the physical. Ebola Treatment Units (ETUs) can be isolating and terrifying environments due to the full-body PPE worn by staff. Modern care models emphasize “humanizing” the ETU—using transparent walls so patients can see outside, allowing protected family visits, and providing psychosocial support to alleviate fear and stigma. This holistic approach improves patient compliance and outcomes.
Send us all your questions or requests, and our expert team will assist you.
A monoclonal antibody is a type of protein made in a laboratory that can bind to substances in the body, including cancer cells or viruses. In the case of Ebola, these antibodies are designed to bind to the virus’s surface, blocking its entry into human cells and flagging it for destruction by the immune system.
No. Antibiotics kill bacteria, not viruses. Because Ebola is a viral disease, antibiotics have no direct effect on it. However, antibiotics are often given to Ebola patients to treat or prevent secondary bacterial infections that can occur because the patient’s immune system is weakened.
No. Because Ebola is highly infectious and lethal, standard hospital laboratories are not equipped to handle samples safely. Samples must be handled in high-containment facilities or using specialized closed systems to protect laboratory staff from exposure to aerosols or droplets containing the virus.
Because malaria symptoms are nearly identical to those of early Ebola, a rapid malaria test is almost always performed alongside the Ebola test. In many outbreak protocols, patients are given antimalarial medication immediately while waiting for Ebola results, to ensure that if they do have malaria, treatment is not delayed.
Contact tracing involves identifying everyone who has had contact with a diagnosed Ebola patient. These contacts are then monitored daily for 21 days. If a contact develops symptoms, they are immediately isolated and tested. This proactive evaluation helps catch new cases early and breaks the chain of transmission.
Your Comparison List (you must select at least 2 packages)
